Showing 6191-6200 of 7769 results for "".
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Study Highlights Potential Minoxidil Shortagehttps://practicaldermatology.com/news/study-highlights-potential-minoxidil-shortage/2462107/Minoxidil may be in short supply at some pharmacies, potentially jeopardizing patients’ efforts to treat hair loss, according to new research in the
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- Tralokinumab Shows Improvements in Dupilumab Patients Up to 52 Weekshttps://practicaldermatology.com/news/tralokinumab-shows-improvements-in-dupilumab-patients-up-to-52-weeks/2462103/The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. Approved in the EU
- Exploring the Sunscreen Paradoxhttps://practicaldermatology.com/news/exploring-the-sunscreen-paradox/2462101/Sunscreen use may provide people with a false sense of security. The so-called sunscreen paradox suggests that individuals with higher levels of sun exposure also tend to use more but not an adequate quantity of sunscreen or other sun-protection measures, providing a false sense of
- Study: Psoriasis Not Caused by Somatic Mutationshttps://practicaldermatology.com/news/study-psoriasis-not-caused-by-somatic-mutations/2462099/Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. Researchers from the Wellcome Sanger Institute in Hinxton, U.K. and collaborators sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated ge
- Psoriasis Pipeline Update: Will An Oral IL-23 Inhibitor Be the Next Psoriasis Blockbuster?https://practicaldermatology.com/news/psoriasis-pipeline-update-will-an-oral-il-23-inhibitor-be-the-next-psoriasis-blockbuster/2462098/Investigational JNJ-2113 is a novel oral interleukin (IL)-23R antagonist peptide that binds with high affinity to the IL-23R. It is the first and only targeted oral peptide designed to block the IL-23 receptor, which underpins the inflammatory response in psoriasis and other IL-23-
- Nemolizumab Continues to Wow in PNhttps://practicaldermatology.com/news/nemolizumab-shows-continued-promise-in-pn/2462095/Nemolizumab monotherapy significantly and rapidly improves itch and skin lesions in patients with prurigo nodularis, with clinically meaningful improvements seen as early as week four, according to results from the OLYMPIA 2 Trial, which appears in the
- Meet Sentient’s Newest Executives...https://practicaldermatology.com/news/meet-sentients-newest-executives/2462094/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, while advancing the